[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366576-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366576-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","garp-expressing-tregs-as-a-source-of-immunosuppressive-tgf-1-in-human-tumors","GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors","","GARP-expressing regulatory T cells (Tregs) are investigated as a source of immunosuppressive TGF-β1 in human tumors. Most cells produce latent TGF-β1, yet only specific cell-type mechanisms activate the cytokine. Using multiplexed immunohistofluorescence and computerized image analysis on 186 tumor samples from five cancer types, the study finds GARP+FOXP3+ cells in 29–75% of tumors and elevated pSMAD2+ TGF-β1 signaling in tumors versus adjacent non-cancerous tissues. Proximity analyses indicate short-range paracrine TGF-β1 signaling, with pSMAD2+ tumor-infiltrating T lymphocytes closer to FOXP3+ cells, supporting GARP+ Tregs as the local source. Anti-GARP:TGF-β1 antibodies could block this local immunosuppression.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/garp-expressing-tregs-as-a-source-of-immunosuppressive-tgf-1-in-human-tumors/366576/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/garp-expressing-tregs-as-a-source-of-immunosuppressive-tgf-1-in-human-tumors/366576.png","ImageObject",300,407,{"name":42,"@type":43},"Franzy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main question addressed in the study?","Question",{"text":63,"@type":64},"Which cells generate the immunosuppressive, active TGF-β1 in human tumors and how that TGF-β1 is activated locally.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was TGF-β1 activation evaluated in tumor samples?",{"text":68,"@type":64},"The study used multiplexed immunohistofluorescence with computerized image analyses, including markers for GARP+FOXP3+ cells and pSMAD2 as a readout of TGF-β1 signaling.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the proximity analysis suggest about the source of TGF-β1?",{"text":72,"@type":64},"In most tumor types, pSMAD2+ tumor-infiltrating T lymphocytes were closer to the nearest FOXP3+ cell, consistent with short-range paracrine TGF-β1 signaling attributed to GARP-expressing Tregs.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366576,1790206128,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Cancer Immunology, Immunotherapy (2025) 74:308 [https://doi.org/10.1007/s00262-025-04157-2](https://doi.org/10.1007/s00262-025-04157-2)  \nGARP‑expressing Tregs as a source of immunosuppressiveTGF‑β1 in human tumors  \nPierre Van Meerbeeck1 · Douae Maatougui1 · Grégoire de Streel1 · Noora Vaherto1 · Etienne Marbaix2 · Frank Aboubakar Nana1,3 · Marc Van den Eynde4,5 · Alix Devaux6 · Javier Carrasco6 · Agnès Noel7 · Nicolas van Baren1 · Sophie Lucas1,8  \nReceived: 15 April 2025 / Accepted: 22 August 2025 / Published online: 13 September 2025 © The Author(s) 2025  \nAbstract  \nMost cells produce latent transforming growth factor-beta 1 (TGF-β1), but only very few activate the cytokine via cell typespecific mechanisms. TGF-β1 favors cancer progression by suppressing anti-tumor T cell responses. Which cells produce this immunosuppressive TGF-β1 in human tumors is unknown. Putative sources include cells expressing the glycoprotein A repetitions predominant (GARP) protein, comprising mostly activated regulatory T cells (Tregs) (GARP+FOXP3+ cells) and blood endothelial cells (BECs). We performed multiplexed immunohistofluorescence and computerized image analyses on 186 tumor samples from 5 cancer types (colorectal, urothelial, lung and breast primary carcinomas and melanoma metastases), compared to patient-matched adjacent non-cancerous tissues. GARP+ Tregs were present in 29–75% of the various types of tumor samples. Their proportion was higher in tumors than non-cancerous tissues but unexpectedly it did not correlate with that of tumor-infiltrating T lymphocytes (TILs) . The density of blood vessels was similar across samples, with more than half expressing GARP. The proportion of cells undergoing TGF-β1 signaling, which express the phosphorylated form of mothers against decapentaplegic homolog 2 (pSMAD2), was approximately twice as high in tumors compared to non-cancerous tissues. In most tumor types, pSMAD2+ TILs were twice closer to the nearest FOXP3+ cell than after random repositioning, at a distance (~ 70 µm) consistent with short-range paracrine TGF-β1 signaling. In contrast, pSMAD2+ non-T cells and pSMAD2 − TILs were not closer to FOXP3+ cells, neither were pSMAD2+ cells (TILs and others) to BECs. We conclude that, in human tumors, GARP-expressing Tregs rather than BECs appear to represent a source of TGF-β1 suppressing nearby TILs. This local immunosuppression could be blocked with anti-GARP:TGF-β1 antibodies, particularly to treat patients with tumors heavily infiltrated by GARP-expressing Tregs.  \nKeywords TGF-β1 · GARP · Regulatory T cell · Tumor infiltrating lymphocyte · Quantitative multiplexed immunohistofluorescence · Immunosuppression  \n* Nicolas van Baren [nicolas.vanbaren@uclouvain.be](nicolas.vanbaren@uclouvain.be)  \n* Sophie Lucas [sophie.lucas@uclouvain.be](sophie.lucas@uclouvain.be)  \n1 de Duve Institute, UCLouvain, Brussels, Belgium  \n2 Department of Pathology, Cliniques Universitaires Saint-Luc, Brussels, Belgium  \n3 Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Belgium  \n4 Institut de Recherche Clinique Et Expérimentale (Pole MIRO), UCLouvain, Brussels, Belgium  \n5 Department of Medical Oncology and Gastroenterology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium  \n6 Grand Hôpital de Charleroi, Charleroi, Belgium  \n7 Laboratory of Tumor and Development Biology, GIGA, ULiège, Liège, Belgium  \n8 WELBIO department, WEL Research Institute, Wavre, Belgium  \nIntroduction  \nCytokines of the transforming growth factor-beta (TGF-β) family control multiple biological processes including embryonic development, angiogenesis, tissue repair and immune responses [1] . The family comprises the TGF-β1, β2 and β3 isoforms, which signal through a common TGF-β receptor (TβR) . While TGF-β2 and β3 play non-redundant roles in development, TGF-β1 is the most important isoform regulating immune responses afterbirth. Defects in TGF-β1 production or signaling lead to autoimmunity a","cbCaijWwR9KSERaA","https://ap.wps.com/l/cbCaijWwR9KSERaA","pdf",2013408,11,"English","# Abstract\n# Introduction\n## TGF-β family roles in immunity and cancer\n## Latent TGF-β1 activation mechanisms and cellular sources\n## Relevance of GARP on regulatory T cells","[{\"question\":\"What is the main question addressed in the study?\",\"answer\":\"Which cells generate the immunosuppressive, active TGF-β1 in human tumors and how that TGF-β1 is activated locally.\"},{\"question\":\"How was TGF-β1 activation evaluated in tumor samples?\",\"answer\":\"The study used multiplexed immunohistofluorescence with computerized image analyses, including markers for GARP+FOXP3+ cells and pSMAD2 as a readout of TGF-β1 signaling.\"},{\"question\":\"What did the proximity analysis suggest about the source of TGF-β1?\",\"answer\":\"In most tumor types, pSMAD2+ tumor-infiltrating T lymphocytes were closer to the nearest FOXP3+ cell, consistent with short-range paracrine TGF-β1 signaling attributed to GARP-expressing Tregs.\"}]","GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors | PDF",1790166176,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7eae10fd229169c556cc6748f8e9fa96.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31ec4400d00774271e9c96be2cd28e86.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b76c70064fcb928c57c9e930616adcb.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d0e83c5e0b96a40b5d9a4782915d14d.webp",980,1301]